Indeed, inhibition of COX2 or EP4 can lead to the restoration of NK functions to reduce the metastatic burden of breast cancers [84], inhibit M2 macrophage differentiation, enhance CTL-mediated cytotoxicity, and drive TME to favor the Th1 immune responses [85,86]. Here, PTGER4 is linked to breast carcinoma.